Targeting TTR amyloidosis at its source.

Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with no FDA-approved treatments. Eidos Therapeutics is working to change that by developing a novel therapeutic, AG10, that targets the disease at its source by stabilizing TTR.

Link to: PatientsLink to: Physicians